S
Stratus Therapeutics
Developing off-the-shelf hematopoietic stem cell (HSC) therapies to treat a broad range of severe and life-threatening diseases
About Stratus Therapeutics
Stratus Therapeutics (Garuda Therapeutics) is at the forefront of regenerative medicine, focusing on developing on-demand hematopoietic stem cell (HSC) and hematopoietic progenitor cell (HPC) therapies. These therapies are designed to serve as universal grafts for patients with serious blood and immune disorders, addressing the challenge of finding fully matched donors. The company's lead product, ST 101, aims to provide durable multilineage engraftment and long-term immune recovery while minimizing the risk of graft versus host disease. Stratus Therapeutics leverages robust preclinical data to support its novel pipeline, which holds the potential to redefine hematopoietic stem cell transplantation and offer curative therapies for patients with limited treatment options. The company operates in the healthcare sector, targeting patients with unmet medical needs and generating revenue through the development and commercialization of its therapeutic products. Avanish Vellanki, with over 20 years of experience in healthcare and investment banking, leads the company in advancing better treatment options for patients.
Source: Dealroom company dataAt a glance
- Status
- Operational
- Founded
- 2021
- Headquarters
- Natick, United States
- Employees
- 17
- Open positions
- None listed
- Dealroom signal
- 61.9/100
- Industry
- Health
- Sub-industry
- Pharmaceutical, BioTechnology
- Sector
- Biotech & Life Sciences, Biotechnology, Stem Cells, Autoimmune, Immune System, Spinout, Biotech and Pharma, proteomics, DT and LS, science-based
- Business model
- Manufacturing
- Client focus
- b2b
Latest news
Press, funding announcements and product moves mentioning Stratus Therapeutics.
Funding history
Company financing events and reported valuations.
| Deal type | Date | Amount | Valuation | Investors | Source |
|---|---|---|---|---|---|
| LATE VCOther financing | Mar 2025 | $50M | $360M | Northpond Ventures · Kyowa Kirin · OrbiMed · Cormorant Asset Management | ↗ |
| SERIES BOther financing | Feb 2023 | $62M | $360M | Aisling Capital · Alexandria Venture Investments · Northpond Ventures · Mass General Brigham Ventures | ↗ |
Growth signals
Latest recorded traffic for Stratus Therapeutics is 480 monthly website visits, down 83.4% over the last three months. Stratus Therapeutics's team declined 57.5% over the past year.
Similar companies
Company identity and context are open; selected comparison metrics preview what is available on the platform.
Investors
From Dealroom's funding and investor records, grouped by the round each investor first entered.
Series A10 investors entered at this stage
Aisling Capital
OrbiMed
Northpond Ventures
Sectoral Asset Management
Ridgeback Capital
Monashee Investment Management
Resilience
Cormorant Asset Management
Mass General Brigham Ventures
Alexandria Venture Investments
Series B and later1 investor entered at this stage
Kyowa Kirin
Other known investors1 additional known investor
Harvard University
Source: Dealroom Talent Intelligence.
Global footprint
team presence
Market sentiment
An AI-synthesised read of the highest-engagement posts about Stratus Therapeutics on X, ranked by likes and reposts, corporate channels excluded.
Reading the room on X — pulling top posts and synthesizing themes…
Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour
See Stratus Therapeutics’s full profile on Dealroom
Request a free trial to see the complete deal history, financials, people graph and growth signals.
Takes under a minute. Already use Dealroom? Log in.